We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · February 02, 2021

Genetic Heterogeneity of MET-Aberrant NSCLC and Impact on the Outcome of Immunotherapy

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
Genetic Heterogeneity of MET-Aberrant Non-Small Cell Lung Cancer and Its Impact on the Outcome of Immunotherapy
J Thorac Oncol 2020 Dec 09;[EPub Ahead of Print], A Kron, M Scheffler, C Heydt, L Ruge, C Schaepers, A Eisert, S Merkelbach-Bruse, R Riedel, L Nogova, RN Fischer, S Michels, DSY Abdulla, S Koleczko, J Fassunke, AM Schultheis, F Kron, F Ueckeroth, G Wessling, J Sueptitz, F Beckers, J Braess, J Panse, C Grohé, M Hamm, HJ Kabitz, K Kambartel, B Kaminsky, S Krueger, C Schulte, J Lorenz, J Lorenzen, W Meister, A Meyer, J Kappes, N Reinmuth, B Schaaf, W Schulte, M Serke, R Buettner, J Wolf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading